FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1602605418> ?p ?o ?g. }

• W1602605418 abstract "Objective To evaluate if individualized cut-off values of brain volume (BV) at baseline can predict cognitive-performance over two years. Background BV-loss correlates with cognitive decline in RRMS-patients. The use of BV-values to predict cognitive-performance, on an individual patient basis, requires evaluation. Methods The expected BV, normalized for head-size (NBV), was calculated for individuals, based on the baseline-characteristics of each patient and the study in which they were enrolled, using a multiple-regression model (pooled intent-to-treat populations; FREEDOMS, N=1272; FREEDOMS II, N=1083; TRANSFORMS, N=1280).Patients were stratified into three groups based on the differences between observed and expected NBV-values: low-NBV(L-NBV):>1 standard deviation(SD) below mean, medium-NBV(M-NBV):within±1SD, and high-NBV(H-NBV):>1SD above mean.The value of PASAT-3 (Paced Auditory Serial Addition Test) at baseline, at month 24(M24) and its change over 24-months were analyzed according to the baseline NBV-groups in the pooled FREEDOMS/FREEDOMS II studies after adjusting for treatment effect. Fingolimod effect vs. placebo was calculated for NBV at baseline. Results NBV was available for 3592 patients (mean±SD NBV:1520cm 3 ±82 cm 3 ). Baseline, T2-volume, age, EDSS, disease duration, and sex significantly affected NBV (all, p PASAT-scores differed in the three NBV-groups at baseline (means: L-NBV=44.9, M-NBV=48.1, H-NBV=50.2,p and M24 (adjusted for treatment arm, means: L-NBV=46.7, M-NBV=49.8, H-NBV=51.8,p C hange in PASAT-score over 24 months (adjusted for baseline PASAT and treatment arm) was significantly different among the three groups (means: L-NBV=+0.35, M-NBV=+1.60, H-NBV=+2.03,p=0.004). In the overall FREEDOMS/FREEDOMS II population, fingolimod had a significant effect on the PASAT-score change (adjusted for baseline-PASAT, +1.15, 95[percnt]CI=+0.53, +1.77,p<0.001). Conclusion Individualized cut-offs derived from baseline NBV-values adjusted for baseline-characteristics are predictive of subsequent cognitive-performance. Fingolimod significantly improved PASAT-score in the pooled FREEDOMS/FREEDOMS II population, based on NBV at baseline. Study supported by Novartis Pharma AG Disclosure: Dr. Sormani has received personal compensation for activities with Allozyne, Merck Serono, Teva Neuroscience, Synthon, Actelion, and Biogen Idec as a consultant and/or speaker. Dr. Kappos has received personal compensation for activities with Actelion Pharmaceuticals. Dr. Cohen has received personal compensation for activities with Biogen Idec, Eli Lilly, Novartis, and Vaccinex as a consultant and/or speaker. Dr. Barkhof has received personal compensation for activities with Bayer Schering Pharma, Sanofi, Genzyme, Biogen Idec, Teva, Merck Serono, Novartis, Roche, Synthon BV, and Janssen Research as a consultant. Dr. Sprenger9s institution has received research support from Novartis, ElectroCore, Genzyme, Actelion, Mitsubishi Pharma Europe, and Biogen Idec. Dr. Meier has received personal compensation for activities with Novartis as an employee. Dr. Haering has received personal compensation for activities with Novartis as an employee. Dr. Tomic has received personal compensation for activities with Novartis as an employee. Dr. De Stefano has received personal compensation for activities with Teva Neuroscience, Bayer, Sanofi-Aventis, Biogen Idec, Novartis, and Merck Serono." @default.
• W1602605418 created "2016-06-24" @default.
• W1602605418 creator A5024199819 @default.
• W1602605418 creator A5031754069 @default.
• W1602605418 creator A5050196672 @default.
• W1602605418 creator A5051313308 @default.
• W1602605418 creator A5053403281 @default.
• W1602605418 creator A5054874316 @default.
• W1602605418 creator A5066096434 @default.
• W1602605418 creator A5074282614 @default.
• W1602605418 creator A5076585111 @default.
• W1602605418 date "2015-04-06" @default.
• W1602605418 modified "2023-09-27" @default.
• W1602605418 title "Normalized brain volume predicts cognitive performance in MS: an analysis of a large cohort from fingolimod phase III studies (P7.284)" @default.
• W1602605418 hasPublicationYear "2015" @default.
• W1602605418 type Work @default.
• W1602605418 sameAs 1602605418 @default.
• W1602605418 citedByCount "0" @default.
• W1602605418 crossrefType "journal-article" @default.
• W1602605418 hasAuthorship W1602605418A5024199819 @default.
• W1602605418 hasAuthorship W1602605418A5031754069 @default.
• W1602605418 hasAuthorship W1602605418A5050196672 @default.
• W1602605418 hasAuthorship W1602605418A5051313308 @default.
• W1602605418 hasAuthorship W1602605418A5053403281 @default.
• W1602605418 hasAuthorship W1602605418A5054874316 @default.
• W1602605418 hasAuthorship W1602605418A5066096434 @default.
• W1602605418 hasAuthorship W1602605418A5074282614 @default.
• W1602605418 hasAuthorship W1602605418A5076585111 @default.
• W1602605418 hasConcept C118552586 @default.
• W1602605418 hasConcept C126322002 @default.
• W1602605418 hasConcept C142724271 @default.
• W1602605418 hasConcept C15744967 @default.
• W1602605418 hasConcept C169900460 @default.
• W1602605418 hasConcept C204787440 @default.
• W1602605418 hasConcept C27081682 @default.
• W1602605418 hasConcept C2776036978 @default.
• W1602605418 hasConcept C2780640218 @default.
• W1602605418 hasConcept C70410870 @default.
• W1602605418 hasConcept C71924100 @default.
• W1602605418 hasConcept C72563966 @default.
• W1602605418 hasConceptScore W1602605418C118552586 @default.
• W1602605418 hasConceptScore W1602605418C126322002 @default.
• W1602605418 hasConceptScore W1602605418C142724271 @default.
• W1602605418 hasConceptScore W1602605418C15744967 @default.
• W1602605418 hasConceptScore W1602605418C169900460 @default.
• W1602605418 hasConceptScore W1602605418C204787440 @default.
• W1602605418 hasConceptScore W1602605418C27081682 @default.
• W1602605418 hasConceptScore W1602605418C2776036978 @default.
• W1602605418 hasConceptScore W1602605418C2780640218 @default.
• W1602605418 hasConceptScore W1602605418C70410870 @default.
• W1602605418 hasConceptScore W1602605418C71924100 @default.
• W1602605418 hasConceptScore W1602605418C72563966 @default.
• W1602605418 hasLocation W16026054181 @default.
• W1602605418 hasOpenAccess W1602605418 @default.
• W1602605418 hasPrimaryLocation W16026054181 @default.
• W1602605418 hasRelatedWork W148018590 @default.
• W1602605418 hasRelatedWork W1482660289 @default.
• W1602605418 hasRelatedWork W1488970921 @default.
• W1602605418 hasRelatedWork W1492770900 @default.
• W1602605418 hasRelatedWork W1549044103 @default.
• W1602605418 hasRelatedWork W1561633407 @default.
• W1602605418 hasRelatedWork W1566750588 @default.
• W1602605418 hasRelatedWork W1574617653 @default.
• W1602605418 hasRelatedWork W1575220270 @default.
• W1602605418 hasRelatedWork W1729832269 @default.
• W1602605418 hasRelatedWork W2064216739 @default.
• W1602605418 hasRelatedWork W2108110322 @default.
• W1602605418 hasRelatedWork W2487043345 @default.
• W1602605418 hasRelatedWork W2530795112 @default.
• W1602605418 hasRelatedWork W2530854562 @default.
• W1602605418 hasRelatedWork W2537138070 @default.
• W1602605418 hasRelatedWork W2554081667 @default.
• W1602605418 hasRelatedWork W2796779240 @default.
• W1602605418 hasRelatedWork W2808356172 @default.
• W1602605418 hasRelatedWork W2898797860 @default.
• W1602605418 hasVolume "84" @default.
• W1602605418 isParatext "false" @default.
• W1602605418 isRetracted "false" @default.
• W1602605418 magId "1602605418" @default.
• W1602605418 workType "article" @default.